Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Change in Inventory: 2016-2025

Historic Change in Inventory for Heron Therapeutics (HRTX) over the last 10 years, with Sep 2025 value amounting to -$2.9 million.

  • Heron Therapeutics' Change in Inventory fell 195.27% to -$2.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.1 million, marking a year-over-year increase of 510.58%. This contributed to the annual value of $11.1 million for FY2024, which is 188.66% up from last year.
  • Per Heron Therapeutics' latest filing, its Change in Inventory stood at -$2.9 million for Q3 2025, which was down 118.34% from $16.0 million recorded in Q2 2025.
  • In the past 5 years, Heron Therapeutics' Change in Inventory registered a high of $16.0 million during Q2 2025, and its lowest value of -$9.1 million during Q3 2022.
  • Over the past 3 years, Heron Therapeutics' median Change in Inventory value was $363,000 (recorded in 2024), while the average stood at $1.4 million.
  • Its Change in Inventory has fluctuated over the past 5 years, first crashed by 599.46% in 2022, then soared by 6,900.00% in 2024.
  • Heron Therapeutics' Change in Inventory (Quarterly) stood at $6.9 million in 2021, then tumbled by 66.08% to $2.3 million in 2022, then slumped by 95.59% to $103,000 in 2023, then spiked by 6,900.00% to $7.2 million in 2024, then plummeted by 195.27% to -$2.9 million in 2025.
  • Its Change in Inventory was -$2.9 million in Q3 2025, compared to $16.0 million in Q2 2025 and $3.8 million in Q1 2025.